Abstract
Background Famotidine has been posited as a potential treatment for COVID-19. We compared the incidence of COVID-19 outcomes (i.e., death; and death or intensive services use) among hospitalized famotidine users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine non-users separately.
Methods We constructed a retrospective cohort study using data from COVID-19 Premier Hospital electronic health records. Study population were COVID-19 hospitalized patients aged 18 years or older. Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any medication containing one of the three drugs on the day of admission. The famotidine non-user group was derived from the same source population with no history of exposure to any drug with famotidine as an active ingredient prior to or on the day of admission. Time-at-risk was defined based on the intention-to-treat principle starting 1 day after admission to 30 days after admission. For each study comparison group, we fit a propensity score (PS) model through large-scale regularized B logistic regression. The outcome was modeled using a survival model.
Results We identified 2193 users of PPI, 5950 users of the hydroxychloroquine, 1816 users of famotidine and 26,820 non-famotidine users. After PS stratification, the hazard ratios for death were as follows: famotidine vs no famotidine HR 1.03 (0.89-1.18); vs PPIs: HR 1.14 (0.94-1.39); vs hydroxychloroquine:1.03 (0.85-1.24). Similar results were observed for the risk of death or intensive services use.
Conclusion We found no evidence of a reduced risk of COVID-19 outcomes among hospitalized COVID-19 patients who used famotidine compared to those who did not or compared to PPI or hydroxychloroquine users.
Competing Interest Statement
AS, SF, RW, PBR are employees of Janssen Research and Development and shareholder of Johnson & Johnson, the product manufacturer of famotidine. JB is an employee and shareholder of Johnson & Johnson
Clinical Protocols
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Reviewed by New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this research project did not involve human subject research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ashoaibi{at}its.jnj.com
SFortin1{at}ITS.JNJ.com
RWeinst1{at}its.jnj.com
JBerlin{at}its.jnj.com
PRyan4{at}its.jnj.com
Disclosures: AS, SF, RW, PBR are employees of Janssen Research and Development and shareholder of Johnson & Johnson, the product manufacturer of famotidine. JB is an employee and shareholder of Johnson & Johnson.
Data Availability
To protect patient privacy, all patient-level data were maintained securely behind institutional firewalls. Analysis code was executed by researchers, which generated only aggregate summary statistics (cohort counts, model coefficients) which were then synthesized in preparation of this manuscript. All aggregate summary statistics produced have been made publicly available at: https://data.ohdsi.org/Covid19EstimationFamotidine/
Abbreviations
- CDM
- Common Data Model
- CI
- Confidence interval
- GERD
- Gastroesophageal reflux disease
- HRs
- hazard ratios
- MDRR
- minimum detectible risk ratio
- OHDSI
- Observational Health and Data Sciences and Informatics
- OMOP
- Observational Medical Outcomes Partnership
- PHD
- Premier Hospital Database (PHD
- PS
- propensity score
- PPI
- proton pump inhibitors
- SMD
- standardized mean differences
